Navigation Links
China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York

TAIAN CITY, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) (''China Biologic'' or the ''Company''), one of the leading plasma-based pharmaceutical companies in the People's Republic of China (''PRC''), today announced that the Company's management will present at the upcoming China Rising Conference hosted by CCG Investor Relations in New York, NY on May 18, 2009 and the 3rd Annual China Dragon Call Conference hosted by Oppenheimer & Co. Inc. on May 19 to 21, 2009.

The date, time and location of China Biologic' presentation at the China Rising Conference is as follows:

        Date:           Monday, May 18, 2009
        Time:           10:30 a.m. to 11:00 a.m. Eastern Time
        Presenter:      Tristan Kuo, Chief Financial Officer of China
        Venue:          The Yale Club
                        50 Vanderbilt Avenue
                        New York, NY 10017

A replay of the webcast will be available for up to one year following the presentation using the same link.

The China Rising Investment Conference hosted by CCG Investor Relations will provide over 250 fund managers and investors access to senior management of a wide range of Chinese growth companies in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy. The conference will include over 30 US-listed Chinese companies and a number of private companies.

Interested parties and investors may find more information for the conference by visiting the website at .

The date, time and location of China Biologic's presentation at the Oppenheimer 3rd Annual China Dragon Call Conference are as follows:

        Date:           Tuesday, May 19, 2009
        Time:           10:15 p.m. to 10:45 p.m. Eastern Time
        Presenter:      Tristan Kuo, Chief Financial Officer of China Biologic
        Venue:          300 Madison Avenue
                        New York City

The China Dragon Call Conference hosted by Oppenheimer & Co. Inc. will provide intimate access to senior management of leading Chinese companies. These discussions will give investors an ability to analyze secular trends, to identify emerging opportunities and to gather insight into China's investment outlook.

All conferences are for institutional clients of Oppenheimer & Co. Inc. and are by invitation only. For more information, please contact Oppenheimer & Co. Inc. institutional sales representative.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the ''Company''), through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., and equity investments in Xi'an Huitian Blood Products Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. is currently the largest non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's blood products are irreplaceable in the application of medical emergencies, and prevention and treatment for various diseases. It sells its plasma-based biopharmaceutical products to hospitals and other healthcare facilities in China.

Safe Harbor Statement

This release may contain certain ''forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are ''forward-looking statements," including statements regarding: the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," ''expects'' or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     China Biologic Products, Inc.
     Tel:   +86-538-6202206

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY office) or
     Mr. Gary Chin
     Tel:   +1-646-213-1909

SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
2. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
3. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
4. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
5. China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief
6. China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results
7. China Breaks Ground on Largest Comprehensive Stem Cell Storage and Processing Facility
8. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
9. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
10. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
11. China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
(Date:11/30/2015)... 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") ... Wong to its Board of Directors to replace Dr. ... a wealth of experience as co-founder of Resverlogix, with expertise ... --> --> Dr. Wong remarked, "I ... directors. Zenith,s long standing expertise in epigenetics and the advanced ...
(Date:11/30/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... presenting at the 8 th Annual LD Micro ... PT. Dr. John N. Bonfiglio a TapImmune ... presentation and will join TapImmune management in meeting with ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to announce ... offered in symposia, oral sessions, workshops, awards, and posters. The core of ... applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food ...
Breaking Biology Technology:
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/17/2015)... 17, 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... and sale of broadly enabling, pressure cycling technology ("PCT")-based ... today announced it has received gross proceeds of $745,000 ... Placement (the "Offering"), increasing the total amount raised to ... additional closings are expected in the near future. ...
Breaking Biology News(10 mins):